UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (883) 883
life sciences & biomedicine (820) 820
humans (779) 779
female (424) 424
animals (418) 418
male (387) 387
tubulin modulators - administration & dosage (355) 355
tubulin modulators - pharmacology (295) 295
tubulin modulators - therapeutic use (272) 272
oncology (248) 248
treatment outcome (206) 206
middle aged (202) 202
mice (199) 199
pharmacology & pharmacy (187) 187
aged (183) 183
paclitaxel - administration & dosage (171) 171
cell line, tumor (167) 167
cancer (163) 163
tubulin (150) 150
cardiovascular system & cardiology (148) 148
tubulin - metabolism (146) 146
cardiac & cardiovascular systems (141) 141
antineoplastic agents - pharmacology (122) 122
microtubules - drug effects (122) 122
tubulins (118) 118
research (109) 109
tubulin modulators - adverse effects (109) 109
analysis (108) 108
colchicine (107) 107
cell proliferation - drug effects (106) 106
adult (105) 105
microtubules - metabolism (103) 103
paclitaxel (101) 101
neoplasms - drug therapy (100) 100
antineoplastic agents - therapeutic use (98) 98
drug-eluting stents (97) 97
dose-response relationship, drug (96) 96
rats (95) 95
apoptosis (94) 94
care and treatment (92) 92
cell biology (92) 92
neurosciences & neurology (91) 91
chemotherapy (90) 90
apoptosis - drug effects (89) 89
neurosciences (89) 89
tubulin modulators - pharmacokinetics (88) 88
abridged index medicus (86) 86
sirolimus - administration & dosage (82) 82
medicine & public health (81) 81
stents (81) 81
tubulin modulators - chemistry (81) 81
breast neoplasms - drug therapy (80) 80
time factors (78) 78
drug therapy (77) 77
proteins (75) 75
pharmacology/toxicology (73) 73
microtubules (72) 72
biochemistry & molecular biology (71) 71
polymerization (71) 71
tumors (71) 71
antineoplastic agents - administration & dosage (70) 70
antimitotic agents (69) 69
antineoplastic agents (68) 68
xenograft model antitumor assays (67) 67
dosage and administration (65) 65
research article (65) 65
clinical trials (64) 64
cells, cultured (63) 63
health aspects (63) 63
physical sciences (63) 63
colchicine - therapeutic use (62) 62
breast cancer (59) 59
chemistry (58) 58
cancer therapies (57) 57
epothilones - therapeutic use (57) 57
science & technology - other topics (57) 57
studies (57) 57
pharmacology (56) 56
antineoplastic agents - adverse effects (55) 55
drug resistance, neoplasm (55) 55
follow-up studies (55) 55
gene expression (55) 55
rats, sprague-dawley (55) 55
multidisciplinary sciences (54) 54
antineoplastic combined chemotherapy protocols - therapeutic use (52) 52
drug administration schedule (52) 52
physiological aspects (52) 52
prospective studies (52) 52
colchicine - administration & dosage (51) 51
medicine (51) 51
stent (51) 51
cell cycle (50) 50
cell cycle - drug effects (49) 49
disease models, animal (49) 49
immunosuppressive agents - administration & dosage (49) 49
cell survival - drug effects (48) 48
ixabepilone (48) 48
paclitaxel - pharmacology (48) 48
antineoplastic agents - pharmacokinetics (47) 47
kinases (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1005) 1005
German (5) 5
Japanese (4) 4
French (2) 2
Portuguese (2) 2
Chinese (1) 1
Russian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
The natural flavonoid fisetin was recently identified as a lead compound that stabilizes endothelial cell microtubules. In this study, we investigated the... 
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Antineoplastic agents | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Molecular neurobiology, ISSN 0893-7648, 12/2017, Volume 54, Issue 10, pp. 7610 - 7619
Journal Article
Pharmaceutical research, ISSN 0724-8741, 3/2015, Volume 32, Issue 3, pp. 910 - 928
To formulate dendrimer-stabilized smart-nanoparticle (DSSN; pD-ANP-f) for the targeted delivery of the highly hydrophobic anticancer drug, Paclitaxel... 
Biochemistry, general | Biomedical Engineering | Biomedicine | cancer cell uptake | Pharmacy | fluorescence imaging | albumin | dendrimer | caspase activity | Medical Law | Pharmacology/Toxicology | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Life Sciences & Biomedicine | Chemistry, Multidisciplinary | Science & Technology | Hemolysis - drug effects | Neoplasms - metabolism | Paclitaxel - metabolism | Paclitaxel - pharmacology | Apoptosis - drug effects | Tubulin Modulators - pharmacology | Humans | Drug Carriers | Dose-Response Relationship, Drug | Nanoparticles | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Microtubules - metabolism | Paclitaxel - toxicity | MCF-7 Cells | Microtubules - drug effects | Surface Properties | Inhibitory Concentration 50 | Tubulin Modulators - administration & dosage | Tubulin Modulators - metabolism | Antineoplastic Agents, Phytogenic - metabolism | Paclitaxel - administration & dosage | Tubulin Modulators - toxicity | Dendrimers - toxicity | Tubulin Modulators - chemistry | Jurkat Cells | Drug Stability | Solubility | Antineoplastic Agents, Phytogenic - chemistry | Technology, Pharmaceutical - methods | Microtubules - pathology | Chemistry, Pharmaceutical | Hep G2 Cells | Antineoplastic Agents, Phytogenic - toxicity | Particle Size | Dendrimers - chemistry | Hydrophobic and Hydrophilic Interactions | Cell Proliferation - drug effects | Kinetics | Antineoplastic Agents, Phytogenic - pharmacology | Neoplasms - pathology | Nanotechnology | Hydrogen-Ion Concentration | Liver cancer | Therapeutics | Fluorescence | Polymerization | Drugstores | Tubulins | Homeopathy | Materia medica and therapeutics | Pharmaceutical sciences | Cancer | Index Medicus
Journal Article
Investigational new drugs, ISSN 1573-0646, 11/2018, Volume 37, Issue 4, pp. 674 - 683
Background Plocabulin (PM060184) is a novel marine-derived microtubule inhibitor that acts as an antitumor agent. This first-in-human study evaluated... 
Plocabulin | Phase I | Medicine & Public Health | PM060184 | Oncology | Solid tumors | Pharmacology/Toxicology | Microtubule inhibitor | First-in-human | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Neoplasms - metabolism | Peripheral Nervous System Diseases - chemically induced | Polyketides - pharmacokinetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Pyrones - blood | Young Adult | Antineoplastic Agents - adverse effects | Tubulin Modulators - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Tubulin Modulators - blood | Tubulin Modulators - adverse effects | Tubulin Modulators - pharmacokinetics | Treatment Outcome | Pyrones - administration & dosage | Neoplasms - drug therapy | Polyketides - adverse effects | Maximum Tolerated Dose | Pyrones - adverse effects | Polyketides - blood | Antineoplastic Agents - blood | Aged | Pyrones - pharmacokinetics | Polyketides - administration & dosage | Antimitotic agents | Complications and side effects | Dosage and administration | Research | Drug therapy | Antineoplastic agents | Tumors | Schedules | Toxicity | Lung cancer | Clinical trials | Neuropathy | Metastases | Thymus | Anticancer properties | Infusion | Tubulin | Pain | Vomiting | Myelosuppression | Cervical carcinoma | Lung diseases | Non-small cell lung carcinoma | Fatigue | Nausea | Fatigue failure | Myalgia | Cervix | Patients | Studies | Inhibitors | Lysis | Antitumor activity | Titration | Index Medicus
Journal Article
Molecular cancer therapeutics, ISSN 1538-8514, 06/2008, Volume 7, Issue 6, pp. 1472 - 1482
Journal Article
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 05/2016, Volume 13, Issue 11, pp. 659 - 673
Journal Article